Rick explains how the FDA's decision in 1992 reopened the door to psychedelic research, leading to a resurgence of studies worldwide. Neil and Chuck delve into the classification of MDMA as a psychedelic and its therapeutic potential, shedding light on the evolving landscape of psychedelic medicine.
